Study summary
A new allosteric pill produced deep responses in heavily pretreated people
What was tested
TERN-701 (now MK-4208 at Merck), a pill that binds the same pocket as asciminib, for chronic-phase CML after several earlier pills.
What they found
- Major molecular responses increased with dose in heavily pretreated people.
- Some responses occurred in people who had already received asciminib.
What it means
One of several next-generation allosteric pills (with ELVN-001) aimed at resistance and tolerability.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.